|
AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
EP2322929B1
(en)
|
2000-11-27 |
2016-04-06 |
Minerva Biotechnologies Corporation |
diagnostics, drug screening and treatment for cancer
|
|
SI2301965T1
(sl)
|
2002-10-16 |
2015-07-31 |
Purdue Pharma L.P. |
Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
|
|
CA2537263C
(en)
*
|
2002-11-27 |
2017-05-30 |
Minerva Biotechnologies Corporation |
Techniques and compositions for the diagnosis and treatment of cancer (muc1)
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
KR20120064120A
(ko)
*
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
|
CA2595778A1
(en)
|
2005-01-28 |
2006-08-03 |
Ramot At Tel Aviv University, Ltd. |
Anti-muc1 .alpha..beta. antibodies
|
|
USRE47223E1
(en)
|
2005-06-20 |
2019-02-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
NZ563370A
(en)
|
2005-06-20 |
2010-10-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US8252740B2
(en)
*
|
2006-01-27 |
2012-08-28 |
The University Of Mississippi Medical Center |
Thermally-targeted delivery of medicaments including doxorubicin
|
|
JP2009533061A
(ja)
*
|
2006-04-14 |
2009-09-17 |
セルセンス， インコーポレイテッド |
細胞の標識を評価する方法
|
|
EP2155248B1
(en)
*
|
2007-04-12 |
2015-06-10 |
The Brigham and Women's Hospital, Inc. |
Targeting abcb5 for cancer therapy
|
|
EP2144628B1
(en)
|
2007-05-08 |
2012-10-17 |
Genentech, Inc. |
Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
|
|
DK2474557T3
(da)
|
2007-07-16 |
2014-11-10 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
|
NZ583318A
(en)
|
2007-07-16 |
2012-07-27 |
Genentech Inc |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
SG187517A1
(en)
|
2008-01-31 |
2013-02-28 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
NZ602675A
(en)
|
2008-03-18 |
2014-03-28 |
Genentech Inc |
Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
EP3978928A1
(en)
|
2008-11-14 |
2022-04-06 |
The Brigham and Women's Hospital, Inc. |
Therapeutic and diagnostic methods relating to cancer stem cells
|
|
US11542328B2
(en)
|
2008-11-14 |
2023-01-03 |
The Brigham And Women's Hospital, Inc. |
Therapeutic and diagnostic methods relating to cancer stem cells
|
|
PT2552959T
(pt)
*
|
2010-03-26 |
2017-04-21 |
Memorial Sloan Kettering Cancer Center |
Anticorpos para muc16 e métodos de utilização dos mesmos
|
|
AU2014271278B2
(en)
*
|
2010-03-26 |
2017-01-19 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to MUC16 and methods of use thereof
|
|
WO2011133555A2
(en)
|
2010-04-20 |
2011-10-27 |
The Research Foundation Of State University Of New York |
Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
|
|
WO2012075173A2
(en)
|
2010-12-01 |
2012-06-07 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
|
US9433686B2
(en)
|
2011-01-31 |
2016-09-06 |
The Regents Of The University Of California |
Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function
|
|
SG10201603411WA
(en)
|
2011-10-28 |
2016-07-28 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
GB201213858D0
(en)
*
|
2012-08-03 |
2012-09-19 |
Mab Design Ltd |
Method
|
|
CN104717980A
(zh)
*
|
2012-08-14 |
2015-06-17 |
米纳瓦生物技术公司 |
干细胞增强疗法
|
|
CN104837502B
(zh)
|
2012-10-12 |
2018-08-10 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
CA2905181C
(en)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
ES2774976T3
(es)
|
2013-04-29 |
2020-07-23 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
|
|
US10059775B2
(en)
*
|
2014-01-29 |
2018-08-28 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
|
|
CN106414726A
(zh)
*
|
2014-04-07 |
2017-02-15 |
米纳瓦生物技术公司 |
抗nme抗体
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
|
CA2965414C
(en)
|
2014-10-29 |
2024-01-09 |
Teva Pharmaceuticals Australia Pty Ltd |
Interferon .alpha.2.beta. variants
|
|
CA2976089C
(en)
|
2015-02-10 |
2026-01-13 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies
|
|
WO2016149485A1
(en)
|
2015-03-17 |
2016-09-22 |
The Regents Of The University Of California |
Novel chemoimmunotherapy for epithelial cancer
|
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
|
CN108026154B
(zh)
|
2015-07-01 |
2022-03-08 |
伊玛提克斯生物技术有限公司 |
用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
|
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
WO2017096247A1
(en)
|
2015-12-04 |
2017-06-08 |
Mayo Foundation For Medical Education And Research |
Methods and vaccines for inducing immune responses to multiple different mhc molecules
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
CN105950647A
(zh)
*
|
2016-05-16 |
2016-09-21 |
浙江理工大学 |
一种高效表达与制备外分泌型人源ca125的方法
|
|
WO2018009811A1
(en)
|
2016-07-08 |
2018-01-11 |
Genentech, Inc. |
Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
|
|
JP7241677B2
(ja)
|
2016-07-19 |
2023-03-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗ｃｄ４７併用療法
|
|
US10617773B2
(en)
|
2016-08-05 |
2020-04-14 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
|
|
CN109862919A
(zh)
|
2016-10-11 |
2019-06-07 |
免疫医疗有限公司 |
抗体-药物缀合物联合免疫介导的治疗剂
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US11319380B2
(en)
|
2018-06-04 |
2022-05-03 |
Precigen, Inc. |
MUC16 specific chimeric antigen receptors and uses thereof
|
|
EP3920693A4
(en)
|
2019-02-04 |
2022-10-05 |
Minerva Biotechnologies Corporation |
ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
|
|
CN116367857A
(zh)
|
2020-06-08 |
2023-06-30 |
米纳瓦生物技术公司 |
抗nme抗体及治疗癌症或癌症转移的方法
|
|
KR20230028796A
(ko)
|
2020-06-26 |
2023-03-02 |
미네르바 바이오테크놀로지 코포레이션 |
항-nme 항체 및 암 또는 암 전이의 치료 방법
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
JP7768775B2
(ja)
*
|
2021-01-14 |
2025-11-12 |
出光興産株式会社 |
ペプチドタグおよびそれを含むタグ付加タンパク質
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|